Cargando…
Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
BACKGROUND: Dual antiplatelet therapy is the standard of care after coronary stent placement but increases the bleeding risk. The effects of proton pump inhibitors (PPIs) on clopidogrel metabolism have been described, but the clinical significance is not yet definitive. We aimed to do an updated met...
Autores principales: | Cardoso, Rhanderson N, Benjo, Alexandre M, DiNicolantonio, James J, Garcia, Daniel C, Macedo, Francisco Y B, El-Hayek, Georges, Nadkarni, Girish N, Gili, Sebastiano, Iannaccone, Mario, Konstantinidis, Ioannis, Reilly, John P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488889/ https://www.ncbi.nlm.nih.gov/pubmed/26196021 http://dx.doi.org/10.1136/openhrt-2015-000248 |
Ejemplares similares
-
Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019) -
Early clinical outcomes as a function of use of newer oral P2Y(12) inhibitors versus clopidogrel in the EUROMAX trial
por: Huber, Kurt, et al.
Publicado: (2017) -
Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials
por: Benjo, Alexandre M, et al.
Publicado: (2014) -
Systematic oral hydration with water is similar to parenteral hydration for prevention of contrast-induced nephropathy: an updated meta-analysis of randomised clinical data
por: Agarwal, Shiv Kumar, et al.
Publicado: (2015) -
Bleeding events and maintenance dose of prasugrel: BLESS pilot study
por: Carrabba, Nazario, et al.
Publicado: (2016)